Yahoo · Sep 18, 2026
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease Drug
AstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
NASDAQ · AZN
AstraZeneca PLC
Healthcare · Drug Manufacturers - General
$166.08
Down-$0.06 (-0.04%)
Updated Sep 21, 2026, 11:12 AM
SID Score
7.6/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 279.95B
- P/E ratio
- 33.06
- Dividend yield
- 0.92%
- 52-week range
- $72.90 – $212.71
- Volume
- 3.06M
- Avg. volume
- 5.47M
Price performance
AZN price history
1M range · 19 trading sessions · Daily adjusted prices
AZN closed at $166.08 after 19 trading sessions, down 0.38% for the selected period.
- Last close
- $166.08
- Period change
- -0.38%
- Period low
- $156.94
- Period high
- $169.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $167.15 | $167.83 | $165.54 | $166.08 | 3.06M |
| Sep 17, 2026 | $164.59 | $166.29 | $164.295 | $166.14 | 3.81M |
| Sep 16, 2026 | $164.21 | $165.42 | $162.02 | $162.89 | 3.86M |
| Sep 15, 2026 | $161.42 | $163.90 | $160.71 | $161.85 | 2.94M |
| Sep 14, 2026 | $164.08 | $164.55 | $162.14 | $163.78 | 3.09M |
| Sep 11, 2026 | $161.43 | $161.51 | $158.13 | $160.17 | 2.23M |
| Sep 10, 2026 | $157.68 | $160.30 | $157.23 | $159.64 | 2.94M |
| Sep 9, 2026 | $158.31 | $159.1301 | $156.74 | $156.94 | 3.87M |
| Sep 8, 2026 | $163.96 | $163.96 | $159.40 | $160.04 | 5.15M |
| Sep 4, 2026 | $162.82 | $163.78 | $161.13 | $162.70 | 3.07M |
| Sep 3, 2026 | $165.64 | $165.74 | $162.24 | $164.77 | 2.43M |
| Sep 2, 2026 | $162.54 | $164.69 | $160.87 | $161.63 | 3.3M |
| Sep 1, 2026 | $163.66 | $164.24 | $161.385 | $162.47 | 2.6M |
| Aug 31, 2026 | $162.70 | $163.75 | $161.95 | $162.13 | 3.07M |
| Aug 28, 2026 | $163.52 | $163.54 | $161.18 | $162.70 | 2.88M |
| Aug 27, 2026 | $165.27 | $165.58 | $163.98 | $164.52 | 2.5M |
| Aug 26, 2026 | $167.46 | $167.89 | $165.17 | $166.27 | 2.68M |
| Aug 25, 2026 | $167.08 | $170.18 | $166.78 | $169.66 | 3.45M |
| Aug 24, 2026 | $164.57 | $167.08 | $163.97 | $166.71 | 2.78M |
Latest AZN news
The latest Smart Investors Daily articles mentioning AZN.
Stock researchCompany · Overview
AZN research
Overview
Company profile and research snapshot.
Company profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $102.67
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Berenberg Bank | Buy | — |
| Jun 26, 2026 | Deutsche | Sell | — |
| Jun 26, 2026 | Jefferies | Buy | — |
| Jun 11, 2026 | Deutsche | Sell | — |
| Jun 9, 2026 | Jefferies | Buy | — |
News briefing
Generated Sep 20, 2026, 9:11 PM
Why Is AZN Moving Sideways Today?
AstraZeneca showed minimal price movement today, down just $0.06 (0.04%), as investors digest a series of positive pipeline developments across its oncology portfolio. The modest decline suggests the market may have already priced in recent positive news, or investors are taking a wait-and-see approach on clinical execution.
Bottom line: AstraZeneca delivered encouraging pipeline news with FDA Priority Review status and Phase III success in lung cancer, yet the stock's flat performance suggests the market is taking a measured stance on execution risks. Investors should monitor upcoming regulatory decisions and Phase III outcomes closely, as approvals could unlock significant upside, while delays or competitive setbacks represent key downside risks to monitor.
Yahoo · Sep 18, 2026
AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success
AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in...
Yahoo · Sep 18, 2026
AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
On September 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary disease. It shows the treatment reduced moderate and severe flare-ups by roughly 30% across a broad patient population, reinforcing the company’s forecast that the drug could generate more […]
Yahoo · Sep 17, 2026
Onco360® Has Been Selected as a National Pharmacy Partner for ETCAMAH™ (camizestrant)
LOUISVILLE, Ky., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca for Etcamah™ (camizestrant), which is indicated for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy, based on a US Food and Drug Administration (FD
AI research layers
Interpretive context generated from the platform’s current data sources.
AstraZeneca PLC Stock Performance
AstraZeneca PLC shares currently trade at $166.08, reflecting a modest 0.69% gain over the past month but a 5.06% decline over the trailing three-month period, per SID market data. On a twelve-month basis, AZN has delivered a substantial return of 114.13%, significantly outperforming broader market indices. The stock trades above both its 50-day moving average of $164.27 and its 200-day moving average of $163.55, indicating a constructive technical posture according to Massive/Polygon data. The 14-day relative strength index stands at 56.5, placing the stock in neutral territory, neither overbought nor oversold. AZN's beta of 0.168 reflects extremely low volatility relative to the broader market, consistent with its defensive healthcare sector positioning. Average daily trading volume registers at approximately 5.47 million shares, supporting adequate liquidity for the company's $279.9 billion market capitalization.
AstraZeneca PLC Valuation Analysis
AstraZeneca PLC currently trades at a price-to-earnings ratio of 33.06, representing a premium valuation relative to the broader healthcare sector, per SID market data. The PEG ratio stands at 4.53, suggesting that the stock's earnings growth rate does not fully support its elevated P/E multiple at current levels. The price-to-book ratio of 6.24 further reflects a significant premium to book value, consistent with a large-cap pharmaceutical company possessing substantial intangible asset value in its drug pipeline. According to SEC filings, AZN offers a dividend yield of approximately 1.56%, providing a modest income component for shareholders. The company's $279.9 billion market capitalization positions it among the largest global pharmaceutical firms. These valuation metrics collectively indicate that the market is pricing in continued revenue and pipeline growth, with the current multiple structure reflecting expectations for sustained earnings expansion across AstraZeneca's oncology and biopharmaceutical portfolios.
Smart Money Activity for AZN
AstraZeneca PLC registers a composite smart money score of 58 out of 100, corresponding to a neutral signal, per SID market data. The institutional component stands at a perfect 25 out of 25, indicating strong positioning and conviction among large institutional holders. In contrast, the dark pool activity score is notably low at 9.0 out of 25, suggesting limited off-exchange accumulation in recent periods. Congressional trading activity scores 12 out of 25, reflecting moderate engagement from elected officials' disclosed portfolios. According to SEC Form 4 filings, insider activity has been modestly positive, with 2 insider transactions recorded over the past 90 days — both classified as purchases with zero sells. The insider sentiment component scores 12.5 out of 25. The divergence between robust institutional ownership signals and subdued dark pool activity creates a mixed but not bearish smart money profile. The exclusive presence of insider buying, per 13F institutional filings, provides a marginally constructive data point regarding management confidence in AstraZeneca's forward outlook.
AstraZeneca PLC Earnings Outlook
AstraZeneca PLC has demonstrated a pattern of exceeding analyst expectations in its most recent reported quarters. According to company earnings reports, the quarter reported on July 27 delivered earnings per share of $2.63 against an estimate of $1.52, representing a positive surprise of $1.11, or approximately 73%. The prior quarter, reported on April 29, showed EPS of $2.58 versus a consensus estimate of $1.53, yielding a $1.05 positive surprise of roughly 69%. These consecutive substantial beats indicate AstraZeneca's operational performance has consistently surpassed Wall Street forecasts. Looking ahead, analyst estimates project EPS of $1.75 for the upcoming April 28 report and $1.44 for the July 28 report. The sequential decline in forward estimates relative to recent actuals warrants monitoring, though the company's track record of surpassing consensus may suggest conservative estimate positioning among analysts covering the stock.
Wall Street Analyst Ratings for AZN
Wall Street analyst coverage of AstraZeneca PLC reflects a divided outlook based on recent ratings activity. Per SID consensus data, Berenberg Bank reiterated a Buy rating on July 13, 2026, reinforcing a positive stance on the company's prospects. Jefferies has also maintained a Buy rating, reiterating on both June 26 and June 9, signaling sustained conviction in AZN's growth trajectory. Conversely, Deutsche Bank has taken a contrarian position, reiterating a Sell rating on both June 26 and June 11, according to Wall Street analyst reports. This creates a notable split among covering analysts, with two firms maintaining bullish recommendations and one firm expressing a bearish view. The divergence centers on differing assessments of AZN's valuation relative to its pipeline potential and earnings sustainability. With the stock's P/E ratio at 33.06, valuation sensitivity appears to be the primary differentiator among analysts. The absence of Hold ratings in recent coverage underscores strong conviction on both sides of the debate.
